Clinical Trials Logo

Cardioversion clinical trials

View clinical trials related to Cardioversion.

Filter by:
  • None
  • Page 1

NCT ID: NCT04468321 Active, not recruiting - Atrial Fibrillation Clinical Trials

Heart Watch Study: a Pragmatic Randomized Controlled Trial

Start date: August 18, 2021
Phase: N/A
Study type: Interventional

This will be a prospective multi-center, randomized, controlled trial of 150 patients conducted to assess the impact of individual use of the Apple Watch compared to the Withings Move on patient-reported and clinical outcomes at 6 months and up to 1 year.

NCT ID: NCT04151966 Completed - Cardioversion Clinical Trials

Myocardial Injury Following Elective Direct Current Cardioversion for Atrial Arrhythmias

Start date: July 22, 2019
Phase:
Study type: Observational

Researchers are trying to determine if heart injury occurs in subjects who undergo direct current cardioversion.

NCT ID: NCT03591627 Recruiting - Atrial Fibrillation Clinical Trials

Left Atrial Thrombus on Transesophageal Echocardiography

LATTEE
Start date: October 1, 2018
Phase:
Study type: Observational [Patient Registry]

The aim of the study is to assess the prevalence of left atrial thrombus in patients with atrial fibrillation (AF) or atrial flutter (AFI), in whom transesophageal echocardiography is performed before AF/AFl cardioversion or ablation.

NCT ID: NCT02742207 Recruiting - Atrial Fibrillation Clinical Trials

Renal Function Post Cardioversion for Atrial Fibrillation

AFCARD-II
Start date: July 11, 2018
Phase:
Study type: Observational

Atrial fibrillation is a common arrhythmia which requires electrical cardioversion in many patients in order to regain sinus rhythm. In a previous retrospective study a complication of acute renal failure was found in 17% of the patients after cardioversion.(The incidence and prognosis of renal dysfunction following cardioversion of atrial fibrillation. Helman Y,...Gilon D et al:Cardiology 2013;124(3);184-9.) Another complication previously described after cardioversion is pulmonary edema. In this prospective study the investigators aim to evaluate the risk of acute renal failure post cardioversion. In addition the investigators would like to evaluate hemodynamic changes, fluid balance and sodium levels in patients post cardioversion as a potential mechanism for both acute renal failure and pulmonary edema post cardioversion. In order to assess hemodynamic changes the investigators will use a non-invasive FDA approved device called NICaS (Non-Invasive Cardiac System). This system calculates cardiac output, cardiac index and peripheral vascular resistance in a non-invasive, fast and accurate way.

NCT ID: NCT01924065 Active, not recruiting - Atrial Fibrillation Clinical Trials

Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation

AFTER-CV
Start date: August 2013
Phase: Phase 3
Study type: Interventional

Patients with atrial fibrillation undergoing cardioversion will be randomized to undergo transesophageal echocardiography or they will receive warfarin for 3 weeks with an international normalized ratio (INR) value between 2.0-3.0. Those who do not want to use warfarin will be given an approved new oral anticoagulant agent istead of warfarin for 3 weeks. If thrombus is detected in left atrium or in left atrial appendage, no cardioversion will be performed. Other patients in the both groups will undergo electrical cardioversion. After the procedures all the patients will be given oral anticoagulant for at least 4 Weeks. All patients will have neurological examination and diffusion magnetic resonance imaging (MRI) at baseline and at postprocedural 7th day. Clinical and subclinical cerebral thromboembolic events detected by diffusion MRI will be recorded. Any bleeding events will also be recorded.

NCT ID: NCT01910779 Recruiting - Atrial Fibrillation Clinical Trials

Optimization of Initial Energy for Cardioversion of Atrial Fibrillation With Biphasic Shocks

OPTIMA
Start date: May 2013
Phase: N/A
Study type: Interventional

Use of higher energy doses (120-150 J) may not offer additional benefits and higher success rate compared with low to moderate initial energy (100-120 J) of biphasic shock for atrial fibrillation cardioversion. In this prospective open-label randomized trial consecutive patients with AF and candidate to AF electrical cardioversion will be randomized to receive 100J or 120 J as initial dose of biphasic shock. Patients will be also randomized in each group to anterolateral or postero-anteriore placement of defibrillator electrodes.